Literature DB >> 15920348

Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan.

Etsuro Orito1, Fuminaka Sugauchi, Yasuhito Tanaka, Takafumi Ichida, Michio Sata, Eiji Tanaka, Takeshi Okanoue, Hiroshi Sakugawa, Hisatsuyo Watanabe, Hiroshi Miyakawa, Shuhei Nishiguchi, Hiromitsu Kumada, Ryuzo Ueda, Masashi Mizokami.   

Abstract

Hepatitis B virus (HBV) genotypes B (HBV/B) and C (HBV/C) are prevalent in Asia. Recently HBV/B has been classified into two subtypes, HBV/Ba which is ubiquitously found in Asia, and HBV/Bj which is specific in Japan. In addition, the frequency of positive HBeAg has been reported to be higher in patients with HBV/Ba than those with HBV/Bj. However, little is known about the differences between patients with various genotypes who developed hepatocellular carcinoma (HCC). In 296 serum samples of HCC patients collected from all over Japan, HBV genotypes were determined with the restriction fragment length polymorphism. HBV/A was detected in 1.0%, HBV/Ba in 4.4%, HBV/Bj in 7.4%, and HBV/C in 86.5%. In the Tohoku district and Okinawa, HBV/Ba, HBV/Bj and HBV/C were found in 6.7, 40.0 and 48.9%, compared to 4.0, 1.6 and 93.2% in the other districts in Japan. HBV/Bj patients were more frequently found in the group older than 65 years while HBV/Ba patients were found in all age groups. The frequency of positive HBeAg in HBV/Bj patients was significantly low compared to that in the other patients. More than 60% of the patients with HCC had cirrhosis as the underlying liver diseases. However, in HBV/Ba patients aged 50 years or younger, 80% of them had chronic hepatitis, while 87.5% of those aged older than 50 years had cirrhosis. These data suggest that great differences exist among patients with HCC infected with different genotypes. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15920348     DOI: 10.1159/000084601

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  8 in total

1.  Clinical features of hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma.

Authors:  Xin Bai; Yu Zhu; Yan Jin; Xia Guo; Gengsun Qian; Taoyang Chen; Jing Zhang; Jinbing Wang; John D Groopman; Jianren Gu; Hong Tu
Journal:  Carcinogenesis       Date:  2010-09-28       Impact factor: 4.944

Review 3.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

4.  Role of viral factors in the natural course and therapy of chronic hepatitis B.

Authors:  Jia-Horng Kao
Journal:  Hepatol Int       Date:  2007-10-12       Impact factor: 6.047

Review 5.  Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.

Authors:  Leonardo Stella; Francesco Santopaolo; Antonio Gasbarrini; Maurizio Pompili; Francesca Romana Ponziani
Journal:  World J Gastroenterol       Date:  2022-06-07       Impact factor: 5.374

6.  Epidemiology of hepatocellular carcinoma in Japan.

Authors:  Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Eiji Tanaka; Kendo Kiyosawa
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China.

Authors:  Weihua Li; Guangyuan Chen; Xianwen Yu; Yongying Shi; Miaoguan Peng; Jianjun Wei
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

8.  Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.

Authors:  Ruksana Raihan; Sheikh Mohammad Fazle Akbar; Mamun Al Mahtab; Kazuaki Takahashi; Junya Masumoto; Shahina Tabassum; Kok Keng Tee; Rosmawati Binti Mohamed
Journal:  PLoS One       Date:  2019-06-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.